| Literature DB >> 27439595 |
Keina Nagakita1, Katsuyoshi Takata1, Kohei Taniguchi1, Tomoko Miyata-Takata1, Yasuharu Sato1, Akira Tari2, Nobuhiko Ohnishi1, Mai Noujima-Harada1, Shizuma Omote1, Naoya Nakamura3, Masaya Iwamuro4, Yoshinobu Maeda5, Hiroyuki Okada4, Mitsune Tanimoto5, Tadashi Yoshino1.
Abstract
The gastrointestinal (GI) tract is the most common primary site of extranodal diffuse large B-cell lymphoma (DLBCL), with approximately one-third of extranodal DLBCL occurring in the GI tract. We investigated the clinicopathological features and immunohistochemically-assessed cell-of-origin of 49 GI DLBCL cases (stomach, 24; small intestine, 10; colon, 15) and also examined the presence of MYD88 L265P as recently this mutation has been frequently identified in ABC-like DLBCL, particularly in extranodal sites. Small intestinal DLBCL was characterized by the preponderance of women (P = 0.041) and elevated LDH (P = 0.002) and soluble interleukin-2 receptor (P = 0.033). Small intestinal DLBCL more frequently showed anemia (P = 0.031) and elevated CRP (P = 0.029) than gastric DLBCL. ABC-like phenotype was seen in 71.4 % cases (stomach, 79 %; small intestine, 70 %; colon, 60 %). MYD88 L265P was detected in 6.1 % cases; all were primary gastric DLBCL with ABC-like phenotype but had no distinct clinicopathological features. In conclusion, GI DLBCL had different clinicopathological features according to the primary site especially in the small intestine. Also, MYD88 L265P had little involvement in GI DLBCL compared with other extranodal DLBCLs, suggesting that its pathogenesis might be different from that of organs with a high frequency of MYD88 L265P.Entities:
Keywords: MYD88 L265P; diffuse large B-cell lymphoma; gastrointestinal tract
Mesh:
Substances:
Year: 2016 PMID: 27439595 DOI: 10.1111/pin.12439
Source DB: PubMed Journal: Pathol Int ISSN: 1320-5463 Impact factor: 2.534